Federal grants to Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California received $69.2 million in federal grants from fiscal 2021 to 2025, across 63 awards. Its largest program was Allergy and Infectious Diseases Research, with $26.7 million. In fiscal 2025 it was awarded $13.7 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$69.2 million
- Awards63
- Awarded in FY 2025$13.7 million
- Largest award$7.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 27 | $12.0 million |
| FY 2022 | 31 | $13.2 million |
| FY 2023 | 22 | $12.6 million |
| FY 2024 | 25 | $17.6 million |
| FY 2025 | 22 | $13.7 million |
Programs that fund Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 16 | $26.7 million |
| Cardiovascular Diseases Research | 12 | $11.8 million |
| Child Health and Human Development Extramural Research | 11 | $11.2 million |
| Military Medical Research and Development | 3 | $5.8 million |
| Trans-NIH Research Support | 4 | $3.8 million |
| Oral Diseases and Disorders Research | 3 | $2.8 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 2 | $2.0 million |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 3 | $1.7 million |
| Cancer Cause and Prevention Research | 1 | $920,030 |
| Mental Health Research Grants | 2 | $906,520 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 59 | $63.0 million |
| Department of Defense | 3 | $5.8 million |
| Department of Commerce | 1 | $496,000 |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Systems epigenomics of persistent bloodstream infection - project abstract persistent bloodstream infections are life-threatening infectious disease emergencies posing significant challenges to effective treatment. Such infections occur when a pathogen is susceptible to an anti-infective agent in VI | Allergy and Infectious Diseases Research | August 10, 2023 | $7.0 million |
| Center for male reproductive epigenomics | Child Health and Human Development Extramural Research | November 18, 2020 | $4.3 million |
| Cross-kingdom vaccine targeting healthcare-associated priority pathogens | Allergy and Infectious Diseases Research | February 2, 2021 | $3.3 million |
| Transcriptional networks governing a. Fumigatus virulence - abstract invasive infections due to aspergillus fumigatus are increasing and are still associated with unacceptably high mortality, even with new therapies. Our understanding of a. Fumigatus infection biology is limited. Among 10,180 predic | Allergy and Infectious Diseases Research | September 22, 2021 | $3.3 million |
| Type i ifn signaling during lung development in down syndrome - project summary/abstract down syndrome (DS), also referred to as trisomy 21, is the most common human chromosomal anomaly, affecting 1 in 700 live births. Although ds can affect many organ systems, lung and heart disease are the leading | Trans-NIH Research Support | September 17, 2021 | $3.3 million |
| Ultra-early surgery for acute spinal cord injury: a prospective trial of timing of surgical decompression | Military Medical Research and Development | August 29, 2024 | $3.0 million |
| Iron uptake and mucormycosis pathogenesis | Allergy and Infectious Diseases Research | July 6, 2021 | $2.8 million |
| Project title wearable multiplex biosensors to monitor exacerbation risk in chronic obstructive pulmonary disease | Military Medical Research and Development | March 20, 2024 | $2.6 million |
| Novel cardiopulmonary exercise testing variables to differentiate neuromuscular deconditioning from disease - project summary cardiopulmonary exercise testing (CPET) is an objective, non-invasive, measure of the integrated function of the pulmonary, cardiovascular and neuromuscular systems. Cpet eva | Cardiovascular Diseases Research | August 30, 2023 | $2.3 million |
| Deciphering immunopathogenesis of mucormycosis to advance risk stratification, diagnosis and management of the disease - project summary/abstract mucorales fungi cause mucormycosis (MCM), a lethal infection in susceptible hosts suffering from diabetic ketoacidosis (DKA), neutropenia, undergoing hema | Allergy and Infectious Diseases Research | July 1, 2025 | $2.2 million |
Questions people ask
How much federal grant money does Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center get?
$69.2 million in 63 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center the most?
The Department of Health and Human Services, with $63.0 million in 59 awards. The Department of Defense and the Department of Commerce follow.
What is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center's largest federal grant?
$7.0 million under Allergy and Infectious Diseases Research, with its first action in the period on August 10, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center?
Its largest are Allergy and Infectious Diseases Research, Cardiovascular Diseases Research and Child Health and Human Development Extramural Research.
Other grant recipients in Torrance
- El Camino Community College District
- California Manufacturing Technology Consulting
- City of Torrance
- Global Clean Energy Holdings Inc
- City of Torrance
- Intelligent Optical Systems, Inc.
- Innosense Corporation
- Cyg Nittany, LLC
Largest federal grant recipients in California · Federal grants in California